Ipamorelin: What the Evidence Actually Shows

Ipamorelin is a synthetic pentapeptide that acts as a selective agonist at the ghrelin receptor (GHS-R1a) — the same receptor class as the ghrelin hormone your stomach produces, and the same target MK-677/ibutamoren works on through a completely different, non-peptide chemical structure. Unlike most unapproved peptides this site covers, ipamorelin has real human trial data behind it — not just rodent pharmacology or in-vitro receptor-binding assays. Two separate, genuinely different human studies exist, and they point in two different directions worth reading precisely rather than blending into one vague "it works" story.

Trial one: yes, it does what it's supposed to, mechanistically

A 1999 human pharmacokinetic/pharmacodynamic study gave ascending IV infusions of ipamorelin to 40 healthy male volunteers — 8 subjects at each of five dose levels — and measured both drug and growth-hormone concentrations directly¹. The pharmacokinetics were dose-proportional, with a short 2-hour terminal half-life¹. The pharmacodynamic finding is the real mechanism-confirming result: ipamorelin triggered a single, distinct pulse of GH release at every dose level tested, peaking at 0.67 hours (about 40 minutes) after infusion and then declining to near-baseline¹. This is a real, quantified human signal that ipamorelin does what it's mechanistically supposed to do — stimulate an episodic GH pulse through the ghrelin receptor — reported here as exactly that and nothing more: a pharmacodynamic proof-of-mechanism, not a clinical-outcomes trial.

Trial two: a real clinical-outcomes trial, and the result was negative

The other human trial is the one worth reading in full rather than skipping to a summary. A phase 2, multicenter, randomized, double-blind, placebo-controlled trial (ClinicalTrials.gov NCT00672074) tested IV ipamorelin — 0.03 mg/kg twice daily — against placebo in 114 patients recovering from bowel-resection surgery, targeting postoperative ileus². The rationale made mechanistic sense: ghrelin-receptor agonists have known promotility effects on the GI tract. The result did not confirm it. Median time to tolerating a solid meal was 25.3 hours on ipamorelin versus 32.6 hours on placebo — numerically faster, but not statistically significant (P=.15)². The trial's own conclusion states this plainly: "There were no significant differences between ipamorelin and placebo in the key and secondary efficacy analyses²." Safety, notably, was clean — 87.5% of the ipamorelin group had any adverse event versus 94.8% on placebo, meaning ipamorelin was not the arm with more reported problems² — this was a well-tolerated drug that simply didn't clear its efficacy bar in this specific indication.

What FDA's own reviewers concluded

FDA's Pharmacy Compounding Advisory Committee formally reviewed ipamorelin (both the free base and the acetate salt) at its October 29, 2024 meeting, considering whether to add either to the federal 503A compounding bulk-substances list. Its own briefing document states directly that there are "no data to support the effectiveness of ipamorelin... for the proposed [subcutaneous] route of administration" for either growth-hormone deficiency or postoperative ileus, and FDA staff proposed against listing. A live, re-confirmed DailyMed search returns zero results for "ipamorelin" — no FDA-approved drug product exists in any form. FDA's current 503A Bulks List, updated May 14, 2026 and re-fetched live for this article, confirms ipamorelin sits in none of its three nomination categories today — it isn't under active safety review, it simply has never cleared the effectiveness bar the agency's own reviewers looked for.

What the FAERS record shows — small numbers, reported anyway

A live openFDA FAERS check for ipamorelin returns 11 total adverse-event reports, with "recalled product administered" (4 reports) the single most common entry, followed by rash (2), and single reports each of upper abdominal pain, acute kidney injury, arthralgia, and elevated blood glucose. Eleven reports is far too small a sample to compute a real incidence rate from — reported here for completeness, not as evidence of a safety signal one way or the other.

What this means if you're considering it

Ipamorelin has a genuinely stronger evidence base than many compounds on this site's roster — a real human PK/PD study confirming it does trigger a measurable GH pulse, and a real, well-conducted phase 2 RCT testing it for a specific clinical indication. That second trial is the one worth sitting with: it found ipamorelin safe but not significantly better than placebo for postoperative ileus, the one outcome it was actually tested against in a controlled human trial. No FDA-approved product exists, and FDA's own compounding reviewers concluded the same thing this trial found — insufficient effectiveness data for the routes and indications examined. If you're weighing ipamorelin against the other GH-axis peptides this site covers, our sermorelin comparison and our three-way comparison with CJC-1295 go deeper on that specific question; our CJC-1295/ipamorelin pairing article covers the two compounds as the market actually sells them together. Once you have an actual dose, our reconstitution calculator does the vial-to-syringe arithmetic.